January 10, 2020
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
SidekickHealth chief executive and cofounder Tryggvi Thorgeirsson; Credit: SidekickHealth
December 16, 2019
Nordic company SideKickHealth has announced today that it entered a strategic partnership with Bayer to provide a digital medication management and lifestyle change platform to patients with Peripheral Arterial Disease (PAD).
While there is no cure, according to the NHS, lifestyle changes and medicine can help reduce the symptoms of patients with PAD. The condition was estimated to affect over...
November 5, 2019
This morning Medopad, an artificial intelligence-enabled patient data collection and analytics platform, landed $25 million in Series B funding. The last round was led by pharma giant Bayer’s venture capital branch Leaps by Bayer.
This new announcement brings the UK-based company’s total funding to $50 million, and comes roughly a year and a half after it closed its $28 million Series A round....
October 14, 2019
German pharma giant Bayer has announced this month that it will be working with 11 additional startups to accelerate the development of digital products improving patients’ health through its G4A Digital Health Partnerships programme.
The startups, which look at oncology, cardiovascular diseases and others, were selected from over 750 applications spanning 65 countries based on the development...
September 18, 2019
Digital diabetes and chronic care company OneDrop has landed $40 million in a Series B funding round led by pharma giant Bayer. This news coincides with the announcement that Bayer inked a deal with the startup, entering into a commercial licensing agreement to use OneDrop’s platform.
This isn’t Bayer’s first foray into digital health. The company has its own accelerator in Germany that was...
May 7, 2019
Life sciences giant Bayer has joined forces with clinical AI technology company Sensyne Health to help develop a national linked patient data capability.
The German firm has signed a memorandum of understanding to be the preferred pharmaceutical partner in a consortium, which includes Microsoft, EY, JP Morgan, and Peel Hunt.
The consortium aims to accelerate the discovery and development of new...
January 23, 2019
Genomic and health data platform LunaDNA’s parent company, LunaPBC, has entered a partnership with Genetic Alliance, a nonprofit focused on delivering research and care opportunities to individuals and communities. Over the next year, LunaDNA will be merging its services with the Genetic Alliance’s engagement platform, strengthening both organizations’ efforts to solicit genetic research data...
April 12, 2018
ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph. The ongoing study is evaluating how these digital products and a Bluetooth-enabled weight scale are perceived by patients, and the feasibility of implementing such devices in future clinical trials run by the...
March 14, 2018
At HIMSS last week, Samsung announced a partnership with Travelers Insurance, Cedars-Sinai Medical Center, Bayer, and AppliedVR around using virtual reality for pain management. Samsung and Travelers will fund a 16-month study of between 90 and 140 patients, conducted at Cedars using technology from Samsung, Bayer, and AppliedVR.
"We just completed a randomized control trial that shows you can...
October 4, 2017
After running its G4A (Grants4Apps) program in Berlin for five years, Bayer is launching a new accelerator program in the United States, the company announced at Health 2.0’s Fall Conference in Santa Clara, California yesterday.
While the plans for the new venture, dubbed G4A Generator, are still being developed, Barton Warner, VP of strategy and portfolio management at Bayer, did share some...